| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Former Director | Director, 10% Owner
3 companies
Chin Mark is a Director at Enliven Therapeutics, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 5 buys and 1 sell.
Estimated insider holdings value: $94.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | PYXS Pyxis Oncology, Inc. | Former Director | Sell | 1,745,761 | $3.05 | $5,324,571.05 | -100% | +6.4% | +24.9% | |
| Oct 13, 2021 | PYXS Pyxis Oncology, Inc. | Director | Buy | 312,500 | $16.00 | $5,000,000.00 | +21.8% | -12.4% | -86.3% | |
| Jul 16, 2021 | ELVN Enliven Therapeutics, Inc. | Director | Buy | 1,333,333 | $6.00 | $7,999,998.00 | +131.9% | -31.7% | -79.3% | |
| Mar 16, 2020 | ELVN Enliven Therapeutics, Inc. | Director, 10% Owner | Buy | 187,500 | $16.00 | $3,000,000.00 | +13.7% | - | - | |
| Oct 30, 2018 | ITRM Iterum Therapeutics Plc | Director | Buy | 58,000 | $6.10 | $353,800.00 | +5.6% | - | - | |
| May 30, 2018 | ITRM Iterum Therapeutics Plc | Director | Buy | 337,606 | $13.00 | $4,388,878.00 | +48.6% | - | - |